ChromeMate® Exhibits Long-Term Safety

Chromium is an essential trace element required for normal protein, fat and carbohydrate metabolism. ChromeMate®, an oxygen-coordinated niacin-bound form of chromium, has previously been demonstrated safe in acute and subchronic (90-day) toxicity studies. Researchers at Creighton University Medical Center examined its long-term safety by administering either 0 (control) or 25 ppm of ChromeMate per day (equivalent to 1000 µg elemental chromium per day in humans, which is five times the recommended dose in humans) to Sprague-Dawley rats over a period of one year. Body weight, feed and water intake, selected organ weights, liver lipid peroxidation and DNA fragmentation, blood chemistry and histopathological evaluations were conducted. At 6, 9 and 12 months of treatment, body weight gain of the ChromeMate-treated groups was significantly reduced by 7.7%, 8.1%  and 14.9% in male rats, and 5.5%, 11.4% and 9.6% in female rats, respectively. At these same time points, ChromeMate treatment did not cause any significant changes in the organ weights, blood chemistry, histopathology, or liver lipid peroxidation and DNA fragmentation, as compared to the control animals. These findings corroborate previous safety studies on ChromeMate and further confirm its long-term safety.

Source: Shara M, Kincaid AE, Limpach AL, Sandstrom R, Barrett L, Norton N, Bramble JD, Yasmin T, Tran J, Chatterjee A, Bagchi M, Bagchi D, Long-term safety evaluation of a novel oxygen-coordinated niacin-bound chromium (III) complex, Journal of Inorganic Biochemistry, 101(7):1059-69, July 2007.